Paige M Bracci1, Yolanda Benavente1, Jennifer J Turner1, Ora Paltiel1, Susan L Slager1, Claire M Vajdic1, Aaron D Norman1, James R Cerhan1, Brian C H Chiu1, Nikolaus Becker1, Pierluigi Cocco1, Ahmet Dogan1, Alexandra Nieters1, Elizabeth A Holly1, Eleanor V Kane1, Karin E Smedby1, Marc Maynadié1, John J Spinelli1, Eve Roman1, Bengt Glimelius1, Sophia S Wang1, Joshua N Sampson1, Lindsay M Morton1, Silvia de Sanjosé1. 1. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA (PMB, EAH); Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d'Oncologia, IDIBELL, Barcelona, Spain, CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain (YB, SdS); Department of Histopathology, Douglass Hanly Moir Pathology, Sydney, Australia, The Australian School of Advanced Medicine, Macquarie University, Sydney, Australia (JJT); Department of Entomology, The Robert H. Smith Faculty of Agriculture, Koret School of Veterinary Medicine Veterinary Teaching Hospital, Hebrew University of Jerusalem, Rehovot, Israel (OP); Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, MN (SLS, ADN, JRC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany (NB); Department of Health Studies, University of Chicago, Chicago, IL (BCHC); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD); Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, Freiburg, Germany (AN); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (EVK, ER); Unit of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden (KES); Biological Hematology Unit, CRB Ferdinand Cabanne, University Hospital of Dijon and University of Burgundy, Dijon, France (MM); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada (JJS); Department of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala, Sweden, Department of Oncology and Pathology, Karolinska Institutet, Stockhol
Abstract
BACKGROUND: Marginal zone lymphoma (MZL), comprised of nodal, extranodal, and splenic subtypes, accounts for 5%-10% of non-Hodgkin lymphoma cases. A detailed evaluation of the independent effects of risk factors for MZL and its subtypes has not been conducted. METHODS: Data were pooled from 1052 MZL cases (extranodal [EMZL] = 633, nodal [NMZL] = 157, splenic [SMZL] = 140) and 13766 controls from 12 case-control studies. Adjusted unconditional logistic regression was used to compute odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Novel findings for MZL subtypes include increased risk for B-cell activating autoimmune conditions (EMZL OR = 6.40, 95% CI = 4.24 to 9.68; NMZL OR = 7.80, 95% CI = 3.32 to 18.33; SMZL OR = 4.25, 95% CI = 1.49 to 12.14), hepatitis C virus seropositivity (EMZL OR = 5.29, 95% CI = 2.48 to 11.28), self-reported peptic ulcers (EMZL OR = 1.83, 95% CI = 1.35 to 2.49), asthma without other atopy (SMZL OR = 2.28, 95% CI = 1.23 to 4.23), family history of hematologic cancer (EMZL OR = 1.90, 95% CI = 1.37 to 2.62) and of non-Hodgkin lymphoma (NMZL OR = 2.82, 95% CI = 1.33 to 5.98), permanent hairdye use (SMZL OR = 6.59, 95% CI = 1.54 to 28.17), and occupation as a metalworker (NMZL OR = 3.56, 95% CI = 1.67 to 7.58). Reduced risks were observed with consumption of any alcohol (EMZL fourth quartile OR = 0.48, 95% CI = 0.28 to 0.82) and lower consumption of wine (NMZL first to third quartile ORs < 0.45) compared with nondrinkers, and occupation as a teacher (EMZL OR = 0.58, 95% CI = 0.37 to 0.88). CONCLUSION: Our results provide new data suggesting etiologic heterogeneity across MZL subtypes although a common risk of MZL associated with B-cell activating autoimmune conditions was found. Published by Oxford University Press 2014.
BACKGROUND:Marginal zone lymphoma (MZL), comprised of nodal, extranodal, and splenic subtypes, accounts for 5%-10% of non-Hodgkin lymphoma cases. A detailed evaluation of the independent effects of risk factors for MZL and its subtypes has not been conducted. METHODS: Data were pooled from 1052 MZL cases (extranodal [EMZL] = 633, nodal [NMZL] = 157, splenic [SMZL] = 140) and 13766 controls from 12 case-control studies. Adjusted unconditional logistic regression was used to compute odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Novel findings for MZL subtypes include increased risk for B-cell activating autoimmune conditions (EMZL OR = 6.40, 95% CI = 4.24 to 9.68; NMZL OR = 7.80, 95% CI = 3.32 to 18.33; SMZL OR = 4.25, 95% CI = 1.49 to 12.14), hepatitis C virus seropositivity (EMZL OR = 5.29, 95% CI = 2.48 to 11.28), self-reported peptic ulcers (EMZL OR = 1.83, 95% CI = 1.35 to 2.49), asthma without other atopy (SMZL OR = 2.28, 95% CI = 1.23 to 4.23), family history of hematologic cancer (EMZL OR = 1.90, 95% CI = 1.37 to 2.62) and of non-Hodgkin lymphoma (NMZL OR = 2.82, 95% CI = 1.33 to 5.98), permanent hairdye use (SMZL OR = 6.59, 95% CI = 1.54 to 28.17), and occupation as a metalworker (NMZL OR = 3.56, 95% CI = 1.67 to 7.58). Reduced risks were observed with consumption of any alcohol (EMZL fourth quartile OR = 0.48, 95% CI = 0.28 to 0.82) and lower consumption of wine (NMZL first to third quartile ORs < 0.45) compared with nondrinkers, and occupation as a teacher (EMZL OR = 0.58, 95% CI = 0.37 to 0.88). CONCLUSION: Our results provide new data suggesting etiologic heterogeneity across MZL subtypes although a common risk of MZL associated with B-cell activating autoimmune conditions was found. Published by Oxford University Press 2014.
Authors: Sophia S Wang; Susan L Slager; Paul Brennan; Elizabeth A Holly; Silvia De Sanjose; Leslie Bernstein; Paolo Boffetta; James R Cerhan; Marc Maynadie; John J Spinelli; Brian C H Chiu; Pier Luigi Cocco; Fiona Mensah; Yawei Zhang; Alexandra Nieters; Luigino Dal Maso; Paige M Bracci; Adele Seniori Costantini; Paolo Vineis; Richard K Severson; Eve Roman; Wendy Cozen; Dennis Weisenburger; Scott Davis; Silvia Franceschi; Carlo La Vecchia; Lenka Foretova; Nikolaus Becker; Anthony Staines; Martine Vornanen; Tongzhang Zheng; Patricia Hartge Journal: Blood Date: 2006-12-21 Impact factor: 22.113
Authors: Vincent James Cogliano; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Lauby-Secretan; Fatiha El Ghissassi; Véronique Bouvard; Lamia Benbrahim-Tallaa; Neela Guha; Crystal Freeman; Laurent Galichet; Christopher P Wild Journal: J Natl Cancer Inst Date: 2011-12-12 Impact factor: 13.506
Authors: Lindsay M Morton; Jennifer J Turner; James R Cerhan; Martha S Linet; Patrick A Treseler; Christina A Clarke; Andrew Jack; Wendy Cozen; Marc Maynadié; John J Spinelli; Adele Seniori Costantini; Thomas Rüdiger; Aldo Scarpa; Tongzhang Zheng; Dennis D Weisenburger Journal: Blood Date: 2007-03-27 Impact factor: 22.113
Authors: I Tramacere; C Pelucchi; M Bonifazi; V Bagnardi; M Rota; R Bellocco; L Scotti; F Islami; G Corrao; P Boffetta; C La Vecchia; E Negri Journal: Ann Oncol Date: 2012-02-22 Impact factor: 32.976
Authors: Silvia de Sanjose; Yolanda Benavente; Claire M Vajdic; Eric A Engels; Lindsay M Morton; Paige M Bracci; John J Spinelli; Tongzhang Zheng; Yawei Zhang; Silvia Franceschi; Renato Talamini; Elizabeth A Holly; Andrew E Grulich; James R Cerhan; Patricia Hartge; Wendy Cozen; Paolo Boffetta; Paul Brennan; Marc Maynadié; Pierluigi Cocco; Ramon Bosch; Lenka Foretova; Anthony Staines; Nikolaus Becker; Alexandra Nieters Journal: Clin Gastroenterol Hepatol Date: 2008-04 Impact factor: 11.382
Authors: Anne Kricker; Bruce K Armstrong; Ann Maree Hughes; Chris Goumas; Karin Ekström Smedby; Tongzhang Zheng; John J Spinelli; Sylvia De Sanjosé; Patricia Hartge; Mads Melbye; Eleanor V Willett; Nikolaus Becker; Brian C H Chiu; James R Cerhan; Marc Maynadié; Anthony Staines; Pierluigi Cocco; Paolo Boffeta Journal: Int J Cancer Date: 2008-01-01 Impact factor: 7.396
Authors: Jean L Koff; Dai Chihara; Anh Phan; Loretta J Nastoupil; Jessica N Williams; Christopher R Flowers Journal: Curr Hematol Malig Rep Date: 2015-09 Impact factor: 3.952
Authors: Dai Chihara; Loretta J Nastoupil; Jessica N Williams; Paul Lee; Jean L Koff; Christopher R Flowers Journal: Expert Rev Anticancer Ther Date: 2015-04-11 Impact factor: 4.512
Authors: Megan M Herr; Sara J Schonfeld; Graça M Dores; Eric A Engels; Margaret A Tucker; Rochelle E Curtis; Lindsay M Morton Journal: Blood Adv Date: 2019-07-09
Authors: Lindsay M Morton; Joshua N Sampson; James R Cerhan; Jennifer J Turner; Claire M Vajdic; Sophia S Wang; Karin E Smedby; Silvia de Sanjosé; Alain Monnereau; Yolanda Benavente; Paige M Bracci; Brian C H Chiu; Christine F Skibola; Yawei Zhang; Sam M Mbulaiteye; Michael Spriggs; Dennis Robinson; Aaron D Norman; Eleanor V Kane; John J Spinelli; Jennifer L Kelly; Carlo La Vecchia; Luigino Dal Maso; Marc Maynadié; Marshall E Kadin; Pierluigi Cocco; Adele Seniori Costantini; Christina A Clarke; Eve Roman; Lucia Miligi; Joanne S Colt; Sonja I Berndt; Andrea Mannetje; Anneclaire J de Roos; Anne Kricker; Alexandra Nieters; Silvia Franceschi; Mads Melbye; Paolo Boffetta; Jacqueline Clavel; Martha S Linet; Dennis D Weisenburger; Susan L Slager Journal: J Natl Cancer Inst Monogr Date: 2014-08